Key Takeaways by Planet Today:
Procedural Revival Opens Door for Evidence Review: The Second Circuit’s July 13, 2026 decision returns over 500 cases to district court for fresh consideration of plaintiffs’ experts, including Harvard epidemiologist Andrea Baccarelli, giving families renewed opportunity to present data on prenatal acetaminophen exposure without the court itself ruling on causation.
Science Remains Contested Territory: While the ruling focuses strictly on admissibility standards and explicitly avoids deciding any general causal link between acetaminophen and autism or ADHD, it keeps alive debates fueled by observational studies showing associations, even as major medical organizations continue to affirm acetaminophen as the preferred option for pain and fever in pregnancy.
Renewed Scrutiny on OTC Safety and Labeling: Kenvue now faces continued litigation pressure, underscoring the pharmace
utical industry’s need for transparent long-term safety data and clear pregnancy warnings amid evolving federal statements and public concern over neurodevelopmental outcomes.Wider Implications for Prenatal Research and Policy: The case highlights how legal proceedings can influence public discourse on environmental and medication factors in autism and ADHD, encouraging expectant parents to consult providers while research bodies pursue deeper investigations into potential contributors. {alertInfo}
 |
| Source: Unsplash |
In the latest development on July 13, 2026, the U.S. Court of Appeals for the Second Circuit revived hundreds of private lawsuits alleging that prenatal use of Tylenol (acetaminophen) caused autism or ADHD in children. The three-judge panel ruled that the lower court had improperly excluded key expert testimony from the plaintiffs, sending the cases back to U.S. District Judge Denise L. Cote for further proceedings on admissibility. The appellate court explicitly stated it was “not deciding whether there is a general causal relationship between acetaminophen and ADHD and/or ASD.”
Kenvue, the maker of Tylenol, responded that “credible, independent science shows no proven link” and vowed to challenge the reliability of the plaintiffs’ experts again at the district level. While some observational studies have reported associations between prenatal acetaminophen exposure and higher risks of autism spectrum disorder and ADHD, leading medical groups such as the American College of Obstetricians and Gynecologists maintain that acetaminophen remains the safest analgesic for pregnant women when used as directed, citing risks of untreated fever and pain as well as limitations in alternative medications.
This legal revival echoes broader scientific inquiries into potential contributors to autism, including environmental and pharmaceutical factors. For more on large-scale research efforts examining autism links, see Planet Today’s coverage of the CDC’s planned study.
The decision provides plaintiffs another chance to advance their claims while Kenvue and retailers defend the product’s safety record. Families and healthcare providers should follow updates from primary court documents and trusted medical sources as the litigation continues.
AFP reports: A US appeals court on Monday vacated the dismissal of hundreds of private lawsuits against Tylenol-maker Kenvue that allege scientifically unproven ties of the painkiller to autism.
Judges at Manhattan’s second circuit of appeals sent the previously dismissed cases back to a lower court for further proceedings, after ruling that a district judge had improperly excluded expert witness testimony.
The plaintiffs argue that Tylenol use during pregnancy can lead to autism or attention deficit hyperactivity disorder in children.
Scientific research has not identified causality between taking the painkiller and the development of those conditions in children.
The issue came into the spotlight last year as US President Donald Trump vehemently urged pregnant women not to take Tylenol over the unsubstantiated link to autism.
Some public health experts have described Trump’s attacks on the drug as unscientific and dangerous.
Acetaminophen is the primary active ingredient in over-the-counter medications including Tylenol.
It is considered the safest option for treating pain and fever in pregnant women, as other medications, including aspirin or ibuprofen, present proven risks to the fetus — as do untreated fevers.
The judges behind Monday’s ruling emphasized that their decision in no way offered scientific advice or the basis for public health policy.
“We are not deciding whether there is a general causal relationship between acetaminophen and ADHD and/or ASD,” they wrote. “And we are certainly not deciding the approach that policymakers concerned with protecting public health should take to regulating the use of acetaminophen.”
Their role, they said, was to determine whether certain expert testimony should have been admitted. And they ruled that “the district court exceeded its discretion” in excluding some of the plaintiffs’ expert witnesses.
A Kenvue spokesperson told AFP that the procedural ruling “does not change the fact that credible, independent science shows no proven link between taking acetaminophen and autism or attention deficit hyperactivity disorder (ADHD).”
“Science matters, and we stand with the many public health and medical professionals who have reviewed the science on this topic and agree. We now have another opportunity to show that the plaintiffs’ experts’ opinions are unreliable and should not be allowed in this case.”
Kenvue was spun off from Johnson & Johnson, which had sold Tylenol for decades, in 2023.
It was announced in 2025 that Kimberly-Clark, the paper and personal care products giant, would acquire Kenvue.